Jeffrey Cummings

Has grant

Joy Chambers-Grundy Professor of Brain Science; Director, Chambers-Gundy Center for Transformative Neuroscience; Co-Director, Pam Quirk Brain Health and Biomarker Laboratory

University of Nevada

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Jeffrey Cummings is the Joy Chambers-Grundy Professor of Brain Science and the Director of the Chambers-Gundy Center for Transformative Neuroscience at the University of Nevada Las Vegas, USA. His research focuses on neurodegenerative disorders, including Alzheimer's disease, with recent articles examining pharmacological interventions, clinical trial methodologies, and biomarker-guided drug development. He also explores agitation in cognitive disorders and the international landscape of Alzheimer's disease clinical trials.

Recent Grants

Grant: Close

Global Alzheimer's Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease

Open Date: 2017-05-01

Close Date: 2023-04-30

Grant: Close

A phase 2 study of intranasal oxytocin for Frontotemporal Dementia

Open Date: 2016-07-01

Close Date: 2020-06-30

Grant: Close

Chronic Traumatic Encephalopathy: Detection, Diagnosis, Course, and Risk Factors

Open Date: 2015-12-15

Close Date: 2022-11-30

Grant: Close

COBRE GRANT

Open Date: 2015-09-01

Close Date: 2020-05-31

Grant: Close

Rasagiline Rescue in Alzheimer's Disease Clinical Trial (Follow-On)

Open Date: 2014-12-01

Close Date: 2016-02-15

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (5)

Jorge Fonseca Cacho

Assistant Professor

University of Nevada

UNITED STATES

View details

Krista L. Lanctôt

CANADA

View details

Frederik Barkhof

University College London

UNITED KINGDOM

View details

Moyra E. Mortby

University of New South Wales

AUSTRALIA

View details

Ana Franceschi, M.D., PH.D.

Assistant Professor

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jeffrey Cummings

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (20)

Monitoring of amyloid related imaging abnormalities: SWI vs T2*-GRE

Brexpiprazole for agitation in clinically relevant patient subgroups: a post hoc analysis of efficacy and safety in patients with agitation associated with dementia due to Alzheimer’s disease

Biomarker-guided decision making in clinical drug development for neurodegenerative disorders

Brief operationalized psychosocial interventions for agitation and psychosis: Use in clinical trials and clinical care

Clinical trials for neuropsychiatric syndromes in major and mild neurocognitive disorders: A CONSORT-based approach

Globalization of Alzheimer’s disease clinical trials: Current characteristics and future goals

Drug repurposing for Alzheimer’s disease and other neurodegenerative disorders

Alzheimer’s Disease: Combination Therapies and Clinical Trials for Combination Therapy Development

Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease

Rarer Dementias, Limited Options, and Unaddressed Needs

Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics

Agitation in cognitive disorders: Progress in the International Psychogeriatric Association consensus clinical and research definition

Reduction and prevention of agitation in persons with neurocognitive disorders: an international psychogeriatric association consensus algorithm

Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders

Distinguishing apathy from depression: A review differentiating the behavioral, neuroanatomic, and treatment‐related aspects of apathy from depression in neurocognitive disorders

Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification

Diabetes: Risk factor and translational therapeutic implications for Alzheimer's disease

Biomarkers for Alzheimer’s Disease: Context of Use, Qualification, and Roadmap for Clinical Implementation

Aducanumab produced a clinically meaningful benefit in association with amyloid lowering

New approaches to symptomatic treatments for Alzheimer’s disease

Collaborators (5)

Jorge Fonseca Cacho

Krista L. Lanctôt

Frederik Barkhof

Moyra E. Mortby

Ana Franceschi, M.D., PH.D.

Make your next move.